Nexmed Logo
 
 
 
Press Releases
NexMed Approved to Sell N.J. Tax Credits [11-18-2008]
NexMed To Report Third Quarter 2008 Financial and Operational Results [11-06-2008]
NexMed Announces $3.5 Million Milestone Payment [10-27-2008]
NexMed Discusses End of Review Meeting for Vitaros® [10-20-2008]
NexMed Receives NASDAQ Listing Qualifications Letter [10-13-2008]
NexMed Announces Decision for NM100060 [8-26-2008]
NexMed Confirms Publication of New Femprox® Data in the Journal of Sexual Medicine [8-04-2008]
NexMed Receives FDA Response for ED Product [7-22-2008]
NexMed to Present at the Collins Stewart 4th Annual Growth Conference [7-08-2008]
NexMed Receives Cash Infusion of $5.75 Million [7-01-2008]
NexMed Confirms Publication on Anti-Fungal Product [6-03-2008]
NexMed Receives Commitment for $3 Million Line of Credit [5-14-2008]
NexMed Confirms Data Presentations on Anti-Fungal Product at Two Pharma Conferences [5-08-2008]
NexMed Facility Receives GMP Certification from Health Canada [5-02-2008]
NexMed Reports 2007 Year End Financial Results [3-12-2008]
NexMed Confirms Acceptance of NDS in Canada [3-05-2008]
NexMed to Present at the Roth Capital 20th Annual OC Growth Stock Conference [2-13-2008]
NexMed Announces Presentation of Data at the 66th Annual Meeting of the American Academy of Dermatology [2-01-2008]
NexMed Appoints Dr. Jay Birnbaum to its Scientific Advisory Board [1-03-2008]
NexMed Confirms FDA Acceptance of NDA for Erectile Dysfunction Product [11-20-2007]
NexMed Reports Third Quarter 2007 Financial Results [11-14-2007]
NexMed Appoints Hem Pandya as Chief Operating Officer [11-02-2007]
Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction [11-01-2007]
NexMed to Present at Acument BioFin 9th Annual Healthcare Conference [10-29-2007]
NexMed Files NDS in Canada [10-22-2007]
NexMed to Present at BioPartnering Europe [10-05-2007]
NexMed to Present at theThinkEquity Partners LLC ThinkClinic Conference [10-01-2007]
NexMed to Present at the New Jersey Technology Council (NJTC) Public/Private Company Showcase [9-28-2007]
NexMed Files NDA for Proprietary Erectile Dysfunction Treatment [9-24-2007]
NexMed Reports Second Quarter 2007 Financial Results [8-14-2007]
NexMed to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Opportunities Conference in New York [7-10-2007]
NexMed Announces Its Inclusion in the Russell Microcap® Index [7-09-2007]
NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product [7-09-2007]
NexMed Appoints Vivian Liu as Chief Executive Officer [6-20-2007]
NexMed To Present at FTN Midwest Securities 2007 Health Care Conference in New York [6-4-2007]
NexMed Reports First Quarter 2007 Financial Results [5-10-2007]
NexMed Reports 2006 Year End Financial Results [3-27-2007]
Webcast Alert: NexMed, Inc. Announces Its Informed Investors Webcast [3-14-2007]
Nexmed Maintains NASDAQ Capital Market System Listing [2-16-2007]
Nexmed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product [1-31-2007]
Nexmed Appoints David S. Tierney M.D. to Board of Directors [1-29-2007]
   
Stock Quotation
Interactive Chart
Annual Report
Fact Sheet
SEC Filings
Press Releases
News and Events
Corporate Governance
Request Additional Information
 
   
 
NexMed is an emerging drug developer that is leveraging its proprietary drug delivery technology to develop a significant pipeline of innovative pharmaceutical products to address large unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT® into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity.